(Nasdaq: GLUE), a clinical-stage biotechnology company developing ... San Antonio Breast Cancer Symposium, held December 10-13 in San Antonio ...
News
- Monte Rosa Therapeutics Presents Preclinical Data at the 2024 San Antonio Breast Cancer ...
- Celcuity Presents Overall Survival Data from Phase 1b Study Evaluating Gedatolisib in ...
... San Antonio Breast Cancer Symposium. 12/11/24 7:05:00 AM ET. $CELC ... biotech company's first drug. His significant commercial experience at ...
- Cantargia and GEICAM Present Updated Phase 1 Clinical Data and New Translational ...
The clinical results along with new biomarker studies will be presented in a poster session at the upcoming San Antonio Breast Cancer Symposium (SABCS) ...
- Eli Lilly's SERD Benefits Endocrine-Resistant Breast Cancer Patients as Single-Agent, Combination
... San Antonio Breast Cancer Symposium on Wednesday. Already registered ... Krystal Biotech Expects CHMP Opinion on Skin Condition Gene Therapy in Early ...
- Kazia Therapeutics to Present Data Highlighting Synergistic Activity Between Paxalisib and ...
... San Antonio Breast Cancer Symposium highlighting the activity the ... Sarepta, Biotech's Regulatory Go-Getter, Signs Standout Rare Disease Deal.